Big Change in Indian Pharma: India Moves Towards Global Standards with CDSCO 30-Day Query Rule
India’s Drug Regulator, the Central Drugs Standard Control Organisation (CDSCO), has now introduced a new, stricter rule in 2026. This rule could significantly change the way pharma companies handle drug approvals.
From May 4 onwards, Pharma companies will have 30 days to respond to any queries that are raised during the drug approval process. If the company fails to reply within this timeframe, their application for drug approval will be rejected. Also, the fee they paid for approval will not be returned.
What has changed?
Until now, many drug applications in India have stayed pending for months, sometimes even years. The reason for this is that companies did not always respond quickly to the regulators’ questions. This slowed down the entire process.
With this new rule, CDSCO is making clear that NO response means no approval.
Also, any older applications that have been pending for over two years are now under examination. If the companies don’t clear the queries within 30 days of notice, those applications will be closed.
Why has CDSCO implemented this New rule?
The move is mainly aimed at speeding up the approval process and clearing the backlogs. Compared to the global regulators like the USFDA and the European Medicines Agency, India’s drug approval process has often been slower. Additionally, it has been less predictable.
By executing a strict timeline, the CDSCO New Rule 2026 is trying to bring more discipline into the system and make the process faster and smoother. The main idea is to move the process faster so that the medicines can reach the patients sooner.
What does this mean for Pharma companies?
For Pharma companies, this is a clear signal to tighten their internal process. This change makes the regulatory and R&D teams stay alert and respond quickly. Moreover, teams need to keep the documents and data ready, so that unnecessary delays can be avoided.
This could also be challenging for smaller companies or those with many pending applications. At the same time, this may also push the companies to focus on the projects that have a clearer path to approval.
As the Indian Pharmaceutical Industry is growing fast, there is increasing pressure to match the global standards, not just in manufacturing, but also in innovation and regulation.
This rule is part of that shift.
While this might feel strict at the beginning, this could help reduce the delays, improve the efficiency, and build trust in the global markets.
